Slingshot members are tracking this corporate initiative:
Neurocrine Biosciences (NBIX) and Xenon Pharmaceuticals(XENE) Announce Agreement to Develop First-in-Class Treatments for Epilepsy
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Dec 02, 2019 Projected Implementation: Q4, 2019 Relevance Tracked Until: Q1, 2020
Don’t see a project related to the strategic initiative you care about?
Related Keywords Epilepsy, Xen901, Nav1.6 Sodium Channel Inhibitor